Yahoo
NYSE - Nasdaq Real Time Price USD

Haleon plc (HLN)

8.57 -1.43 (-14.30%)
At close: 4:00:02 PM EDT
8.60 +0.03 (+0.35%)
After hours: 4:06:36 PM EDT
Trade Haleon on Coinbase
HLN Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for HLN
  • Previous Close 10.00
  • Open 8.55
  • Bid 8.50 x 6710000
  • Ask 8.64 x 4380000
  • Day's Range 8.38 - 8.75
  • 52 Week Range 8.38 - 11.28
  • Volume 56,761,031
  • Avg. Volume 14,972,895
  • Market Cap (intraday) 37.688B
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) 17.49
  • EPS (TTM) 0.49
  • Earnings Date Jul 30, 2026
  • Forward Dividend & Yield 0.20 (1.98%)
  • 1y Target Est 11.93
  • Morningstar Rating Rating available with Stock Picks access

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

www.haleon.com

24,535

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

HLN
13.29%
FTSE 100 (^FTSE)
7.96%

1-Year Return

HLN
4.16%
FTSE 100 (^FTSE)
9.90%

3-Year Return

HLN
16.37%
FTSE 100 (^FTSE)
47.05%

5-Year Return

HLN
15.65%
FTSE 100 (^FTSE)
48.14%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 2.75B
Earnings --
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
1B
2B
0.0%

Analyst Insights

View More

Analyst Price Targets

10.00
11.93 Average
8.57 Current
13.77 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 1/23/2026
Analyst Barclays
Rating Action Upgrade
Rating Overweight
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.55%

  • Return on Assets (ttm)

    5.08%

  • Return on Equity (ttm)

    10.09%

  • Revenue (ttm)

    11.15B

  • Net Income Avi to Common (ttm)

    1.62B

  • Diluted EPS (ttm)

    0.49

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    826M

  • Total Debt/Equity (mrq)

    50.20%

  • Levered Free Cash Flow (ttm)

    1.8B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: